Ovarian Cancer Gloria S. Huang, M.D. Assistant Professor Department of Obstetrics & Gynecology and Women ’ s Health Division of Gynecologic Oncology Albert.

Slides:



Advertisements
Similar presentations
Update on Ovarian Cancer
Advertisements

Advances and Emerging Therapy for Lung Cancer
Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.
FACT:FACT: Ovarian cancer, the deadliest of the gynecologic cancers… Ovarian cancer, the deadliest of the gynecologic cancers…
SURGICAL APPROACH TO GYNAECOLOGICAL CANCERS
Gynecologic Cancers Presented by: Michael Goodheart, MD Assistant Professor Gynecologic Oncology The University of Iowa Hospitals & Clinics Understanding,
Tim Broadhead Consultant Gynaecologist & Gynaecological Oncologist
‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.
SURVIVORS TEACHING STUDENTS: SAVING WOMEN’S LIVES®
A significant increase in the incidence of endometrial cancer. This increased incidence of endometrial cancer has been widely interpreted to be a result.
April 6, o What is cancer? o Cancer statistics o Cancer prevention and early detection o Cancer disparities o Cancer survivorship o Cancer research.
OVARIAN AND CERVICAL CANCER: ARKANSAS STATISTICS Nancy Andrews Collins, M.D., MBA Associate Professor Department of Obstetrics and Gynecology College of.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
SURGICAL MANAGEMENT OF PRIMARY EPITHELIAL OVARIAN CANCER Robert P Edwards M.D Professor of Obstetrics, Gynecology, Reproductive Sciences, and Immunology.
22/10/1436. Addar Professor Gyneoncologist OB/GYN Dept. KKUH and College of Medicine MKing Saud University.
Ovarian cancer….. in 15 minutes
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture By: Reem Sallam, MD, MSc, PhD.
Management of Gynaecological Cancers. Gynaecological Cancers in NSW 1180 new cases in % of all new cancer diagnoses Crude incidence rate 35.3 per.
Focus on Ovarian Cancer (Relates to Chapter 54, “Nursing Management: Female Reproductive Problems,” in the textbook) Copyright © 2011, 2007 by Mosby, Inc.,
Dr.Yousefi Gynecologist Oncologist Surgical Staging Conservative Surgery Cytoreduction Surgery Optimal Cytoreduction Intraperitoneal Chemotherapy Neoadjuvant.
Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Cancer Ignace Vergote, MD PhD University Hospitals Leuven, Belgium IGCS Santa.
Early Detection Is Your Best Protection. Breast Cancer Statistics for Women A woman has a one in eight chance of developing breast cancer in her lifetime.
Ovarian Cancer National Alliance Ovarian Cancer: What All Women Need to Know.
Ovarian Cancer May 2007 Dr Anna Winship Guy’s & St. Thomas’ NHS Trust Click Here For First Question Oncology Registrars’ Forum “Best of Five”
Fallopian Tube and Ovarian Malignancy Schwartz's Principles of Surgery Chapter 41. Gynecology.
BY DR. KHANSA IQBAL SENIOR REGISTRAR GYNAE UNIT-II.
Quang Truong Mr. Kashub 2nd Session
Computed tomography scan of the abdomen shows a large cystic mass in the abdomen and pelvis without solid tissue or septations (measurement: 43×20×31-cm.
4% of all female cancers 25% of all gynecologic cancers life time risk: 1/70 ¾ advanced stage most lethal Epithelial Ovarian Cancer:
Management of ovarian cysts
Endometrial Carcinoma
Are there benefits from chemotherapy to early endometrial cancer
Primary Debulking for Bulky Advanced Stage Ovarian Cancer Ginger J. Gardner, MD Director, Survivorship Program Gynecology Service, Department of Surgery.
10 Minutes Talk 吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.
Lymphadenectomy in Epithelial Ovarian Cancer
Session Fertility and Pregnancy FL-BBM Specific questions Risk of premature ovarian failure Ability to become pregnant Safety of pregnancy.
Breast Cancer: The Profile Ma. Belen E. Tamayo,M.D. Medical Oncologist Makati Medical Center The Medical City.
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
By: Maureen Jaminal BIOL 316
Introduction Ignace Vergote, MD Department of Obstetrics and Gynaecology Gynaecologic Oncology Catholic University of Leuven Leuven, Belgium.
Dr. Saadeh Jaber OBGYN consultant Epidemiology Second most common gynecological cancer. >35, median 70 It accounts for deaths more than cancer of.
Gynecological Malignancies. Gynecologic malignancies account for 15% of all cancers in women. Gynecologic malignancies account for 15% of all cancers.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Survivors Teaching Students: Saving Women’s Lives®
Malignant & Pre-malignant Diseases of the Endometrium Jose B Moran MD Assistant Professor III Section of Gynecologic Oncology Department of Obstetrics.
Mark Browning, M.D. IUSME.  22,000 Cases  14,000 Deaths  Overall Survival Rate is 35%  Survival Rate Depends on Stage.
Metastatic Tumors of Ovary. METASTATIC TUMOR FROM BREAST CANCER both ovaries replaced by pale, rather nodular tumor, with breast cancer cells arranged.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture Dr. Usman Ghani.
Debulking in Ovarian Cancer Ashraf Fawzy Nabhan Assistant Prof. of Obstetrics & Gynecology Ain Shams University, Cairo, Egypt.
Department of Surgical, Oncological and Oral Sciences U.O.C Medical Oncology Director: Prof A. Russo Ovarian cancer Case Report 1 Dr. Lorena Incorvaia,
Gynecologic Oncology New or Old subspecialty Samir Fouad Khalaf Professor OBGYN Al-Azhar University President
Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.
Ovarian Cancer aka “The disease that whispers” Statistics The average age when ovarian cancer is detected in women is 56.3 years. Less than 1 out of.
Clinical and Research Updates in Gynecologic Oncology
“Living Your Best After Cancer: You and Your Primary Care Doctor Working Together" Mary Helen Hackney, MD Associate Professor of Hematology/Oncology at.
Gazi ABDULHAY, Sebile GÜLER ÇEKİÇ
Dose dense chemotherapy in the adjuvant treatment of ovarian cancer
Dr . Saadeh Jaber OBGYN consultant 2010
Figure #1 Overall survival Figure #2 Disease free survival
Male and Female Reproductive Health Concerns
Survivors Teaching Students: Saving Women’s LivesSM
What is the role of genetic testing in patients with ovarian cancer?
GEMSTONE Educational Case Summary
Neoadjuvant Adjuvant Curative Palliative
Ovarian Cancer-Route to Diagnosis
Ovarian Cancer Ovarian Cancer only affects women.
Presentation transcript:

Ovarian Cancer Gloria S. Huang, M.D. Assistant Professor Department of Obstetrics & Gynecology and Women ’ s Health Division of Gynecologic Oncology Albert Einstein College of Medicine Montefiore Medical Center Albert Einstein Cancer Center

Who gets it? What are the signs and symptoms? How do you work it up? How do you treat it? What are the chances of survival? Ovarian Cancer

Ovarian Cancer: U.S. Epidemiology Eighth most common cancer among women –Estimated 20,180 new cases in 2006 Lifetime risk of getting ovarian cancer is approximately 1 in 67 (1.5%) Accounts for 3% of cancers in women American Cancer Society 2006

Ovarian cancer: U.S. Epidemiology 5th most common cause of cancer death in women Estimated 15,310 deaths in 2006 Lifetime risk of dying from ovarian cancer is 1 in 95 (1%)

Histology 85% Epithelial –Serous carcinoma-most common –Endometrioid –Mucinous carcinoma –Clear cell carcinoma 5% Germ Cell 10% Sex cord Stromal

Ovarian Cancer

Ovarian Cancer: Risk Factors IncreaseDecrease AgeOCPs Family historyPregnancy Infertility/low parity Tubal ligation Personal cancer history Breast-feeding

Hereditary factors BRCA 1 and BRCA 2 –10% of ovarian cancers –Lifetime risk 40-50% HNPCC –1% of ovarian cancers

Who gets it? What are the signs and symptoms? How do you work it up? How do you treat it? What are the chances of survival? Ovarian Cancer

Ovarian Cancer: Symptoms 95% of women DO report symptoms. Symptoms can be vague and not gynecologic: –Abdominal bloating, increased girth –Fatigue –Gastrointestinal disturbances –Urinary symptoms –Abdominal/pelvic pain –Menstrual irregularities –Increased flatulence

Who gets it? What are the signs and symptoms? How do you work it up? How do you treat it? What are the chances of survival? Ovarian Cancer

Ovarian Cancer: Diagnostic Modalities Rectovaginal pelvic exam TVS and/or CT scan or MRI CA-125 If diagnosis uncertain, laparoscopy may be useful diagnostic tool Surgical exploration

Normal Ovary

Ovarian Cancer

Who gets it? What are the signs and symptoms? How do you work it up? How do you treat it? What are the chances of survival? Ovarian Cancer

Ovarian Cancer: Surgical Rx for Early Stage Disease Optimal therapy: TAH BSO + staging (including pelvic and PALN) In younger women, reproductive conservation may be appropriate Approximately 30% will have histologic evidence of metastatic disease

Ovarian Cancer: Staging by Surgical Specialty Evaluation of completeness of surgical staging Nearly half of women with early ovarian cancer were inadequately staged by general Ob/Gyns or General Surgeons SurgeonComplete Staging Gyn/Onc97% Ob/Gyn52% Surgeon35% Source: McGowen et al. Ob/Gyn 1985

Ovarian Cancer: Surgical Treatment for Advanced Disease Significant survival advantage for women optimally cytoreduced Procedures may include: –En bloc resection of uterus, ovaries and pelvic tumor –Omentectomy –Bowel resection –Removal of diaphragmatic and peritoneal implants –Splenectomy, appendectomy

Ovarian Cancer: Survival by Residual Disease GOG Protocols (PR) 52 and 97

Ovarian Cancer: Chemotherapy Almost all patients should receive adjuvant chemotherapy with platinum and a taxane >70% response rate I.P. chemo in optimally debulked pts Many new agents being tested Encourage clinical trial participation

Taxol and ovarian cancer McGuire W.P. et al. New Engl J of Med, 334 (1996)

Who gets it? What are the signs and symptoms? How do you work it up? How do you treat it? What are the chances of survival? Ovarian Cancer

Ovarian Cancer: Follow-up Healthcare RV pelvic exam and CA-125 q 3-4 mo x 2 years, q 6 mo for years 3-5 CT scan for symptoms General health maintenance (mammography, Pap smear, bone density, colon-rectal screening, cholesterol, etc.) Discuss HRT, diet, exercise

Ovarian Cancer: Recurrence 75% of patients relapse Treatment options include: –Secondary cytoreduction –Retreatment with platinum/taxane –Second-line therapies, including chemo, radiation, immunologic, gene therapies –Encourage clinical trials

Ovarian Cancer: U.S. Patterns of Care Stage Appropriate Treatment I10% II15% III71% IV53% 785 women with ovarian cancer studied Munoz JCO 1997

Ovarian Cancer: Importance of Surgeon 1,866 women with ovarian cancer Significant advantage for those women managed by Gynecologic Oncologist –More likely to have optimal cytoreduction –Reduction in death by 25% (p= 0.005) compared to Ob/Gyn and General Surgeons Junor et al, Brit J Ob/Gyn, 11/99

Ovarian Cancer: Stage Distribution and 5-year Survival StagePercentSurvival I24%95%95% II6%65% III55%15-30% IV15%0-20% Overall50% American Cancer Society 2002

Relative Survival: Ovarian & Breast Cancers Five-Year Relative Survival Rates by Stage at Diagnosis StageOvaryBreast Local93%97% Regional55%76% Distant25%21% All Stages50%84%

Ovarian Cancer: Future Directions Cost-effective screening Early detection Prevention Reversing chemoresistance Targeted therapies Immunotherapy Gene therapy